Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience

Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience

Background: Hepatoblastoma (HB) is the most common liver malignancy in children. There is no standard of care for management of relapsed/refractory HB (rrHB) and reports in the literature are limited. Objective: To describe presenting features, biology, treatment strategies, and outcomes for pediatr...

Full description

Bibliographic Details
Main Authors: Katherine M. Somers, Rachel Bernstein Tabbouche, Alexander Bondoc, Alexander J. Towbin, Sarangarajan Ranganathan, Greg Tiao, James I. Geller
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Cancers
Subjects:
hepatoblastoma
relapsed hepatoblastoma
cisplatin
pediatric liver tumors
Online Access:https://www.mdpi.com/2072-6694/15/15/3921

Similar Items

Similar Items